Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2752-2761

  O'Day, Steven J ^a   Gammon, Guy ^a   Boasberg, Peter D ^a   Martin, Maureen A ^a   Kristedja, Tim S ^a   Guo, Matthew ^a   Stern, Stacey ^a   Edwards, Shirley ^a   Fournier, Patricia ^a   Weisberg, Monica ^a   Cannon, Maureen ^a   Fawzy, Nancy W ^a   Johnson, Timothy D ^a   Essner, Richard ^a   Foshag, Leland J ^a   Morton, Donald L ^a  

^a SAINT JOHN'S HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032850026     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2752     Document Type: Article

References (36)

1. Balch CM: Cutaneous melanoma: Prognosis and treatment results worldwide. Semin Surg Oncol 8:400-414, 1992
2. Balch CM, Soong SJ, Murad TM: A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-134, 1983
3. Barth A, Warnek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
4. Legha SS: Current therapy for malignant melanoma. Semin Oncol 16:34-44, 1989
5. Anderson C, Buzaid A, Legha S: Systemic treatments for advanced cutaneous melanoma. Oncology 9:1149-1158, 1995
6. Del Prete SA, Maurer L, O'Donnell J, et al: Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403-1405, 1984
7. McClay EF, Mastrangelo MJ, Berd D, et al: Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 50:553-556, 1992
8. McClay EF, McClay ME: Tamoxifen: Is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12:617-626, 1994
9. Legha SS, Ring S, Papadopoulos N, et al: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64:2024-2029, 1989
10. Lakhani S, Selby P, Bliss JM, et al: Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. Br J Cancer 61:330-334, 1990
11. Hill GJ, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: Late results after complete response to chemotherapy. Cancer 53:1299-1305, 1984
12. Ahmann DL, Creagan ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:224-227, 1989
13. Legha SS: The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 24:S24-S31, 1997 (suppl 4)
14. Creagan ET, Schaid DJ, Ahmann DL, et al: Recombinant interferon in the management of advanced malignant melanoma. Am J Clin Oncol 11:652-659, 1988
15. Kirkwood JM: Studies of interferons in the therapy of melanoma. Semin Oncol 18:83-90, 1991
16. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J Am Med Assoc 271:907-913, 1994
17. Atkins MD, Lotze M, Wiernik P, et al: High dose IL-2 therapy alone results in long-term durable complete responses in patients with metastatic melanoma. Proc Am Soc Clin Oncol 16:494a, 1997 (abstr 1780)
18. Richards J, Mehta N, Schroeder L, et al: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343, 1992
19. Khayat D, Borel C, Tourani JM, et al: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173-2180, 1993
20. Flaherty LE, Robinson W, Redman BG, et al: A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 71:3520-3525, 1993
21. Legha SS, Ring S, Eton O, et al: Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center Experience. Cancer J Sci Am 3:S9-S15, 1997
22. Legha SS, Ring S, Bedikian A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 7:827-835, 1996
23. Antoine EC, Benhammouda A, Bernard A, et al: Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12:1553-1560, 1994
24. Buzaid AC, Legha SS: Combination of chemotherapy with interleukin-2 and interferon-alpha for the treatment of advanced melanoma. Semin Oncol 6:23-28, 1994 (suppl 14)
25. Antoine EC, Benhammouda A, Bernard A, et al: Salpetriere Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 3:S16-S21, 1997
26. Legha S, Ring S, Eton O, et al: Durable complete responses (CRs) in metastatic melanoma treated with biochemotherapy using cisplatin + vinblastine + DTIC (CVD) and Il-2 + interferon-alpha (INF-alpha). Proc Am Soc Clin Oncol 14:412, 1995 (abstr 1305)
27. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
28. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16:1752-1759, 1998
29. Keilholz U, Scheibenbogen C, Tilgen W, et al: Interferon-alpha and interleukin-2 in the treatment of malignant melanoma: Comparison of two phase II trials. Cancer 72:607-614, 1993
30. Keilholz U, Goey SH, Punt CJA, et al: Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol 15:2579-2588, 1997
31. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
32. Thompson JA, Gold PJ, Fefer A: Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol 24:S44-S48, 1997 (suppl 4)
33. Thompson JA, Gold PJ, Markowitz DR, et al: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3:S29-S34, 1997
34. Margolin K, Flaherty L, Sondak V, et al: Phase II Study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol 16:664-669, 1998
35. Rusthoven J, Quirt I, Iscoe NA, et al: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2083-2090, 1996
36. O'Day SJ, Martin M, Boasberg P, et al: Escalating doses of tamoxifen in a phase I/II trial of concurrent biochemotherapy with decrescendo interleukin-2, and filgrastim (G-CSF) support in patients with metastatic melanoma. Proc Am Soc Clin Oncol 17:508a, 1998 (abstr 1957)